Cargando…

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia

Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among K...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hun-Ju, Chuang, Meng-Ni, Chu, Chiao-Lun, Wu, Pei-Lin, Ho, Shu-Chen, Kuo, Ho-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037584/
https://www.ncbi.nlm.nih.gov/pubmed/33808075
http://dx.doi.org/10.3390/jcm10071381
_version_ 1783677177957449728
author Yu, Hun-Ju
Chuang, Meng-Ni
Chu, Chiao-Lun
Wu, Pei-Lin
Ho, Shu-Chen
Kuo, Ho-Chang
author_facet Yu, Hun-Ju
Chuang, Meng-Ni
Chu, Chiao-Lun
Wu, Pei-Lin
Ho, Shu-Chen
Kuo, Ho-Chang
author_sort Yu, Hun-Ju
collection PubMed
description Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among KD patients. Therefore, the aim of this study was to assess the difference in myopic incidence between Kawasaki disease (KD) patients treated with aspirin and intravenous immunoglobulin (IVIG). Materials and methods: We carried out a nationwide retrospective cohort study by analyzing the data of KD patients (ICD-9-CM code 4461) from Taiwan’s National Health Insurance Research Database (NHIRD) during the period of 1996–2013. Results: A total of 14,102 diagnosed KD were found in Taiwan during the study period. After excluded missing data, treatment strategy and age distribution, a total of 1446 KD patients were enrolled for analysis including 53 of which received aspirin (without IVIG) and 1393 of which were treated with IVIG. Patients who had myopia, astigmatism, glaucoma, cataract, etc. prior to their KD diagnosis were excluded. The age range was 0 to 6 years old. According to the cumulative curves, our results demonstrated that the myopic incidence in the IVIG group was significantly lower than the aspirin group (hazard ratio: 0.59, 95% confidence intervals: 0.36~0.96, p = 0.02). Treatment with IVIG for KD patients may have benefit for myopia control. Conclusion: Compared to aspirin, IVIG may decrease the myopic risk in KD patients. However, it needs further investigation including clinical vision survey of myopia due to the limitations of this population-based study.
format Online
Article
Text
id pubmed-8037584
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80375842021-04-12 Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia Yu, Hun-Ju Chuang, Meng-Ni Chu, Chiao-Lun Wu, Pei-Lin Ho, Shu-Chen Kuo, Ho-Chang J Clin Med Article Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among KD patients. Therefore, the aim of this study was to assess the difference in myopic incidence between Kawasaki disease (KD) patients treated with aspirin and intravenous immunoglobulin (IVIG). Materials and methods: We carried out a nationwide retrospective cohort study by analyzing the data of KD patients (ICD-9-CM code 4461) from Taiwan’s National Health Insurance Research Database (NHIRD) during the period of 1996–2013. Results: A total of 14,102 diagnosed KD were found in Taiwan during the study period. After excluded missing data, treatment strategy and age distribution, a total of 1446 KD patients were enrolled for analysis including 53 of which received aspirin (without IVIG) and 1393 of which were treated with IVIG. Patients who had myopia, astigmatism, glaucoma, cataract, etc. prior to their KD diagnosis were excluded. The age range was 0 to 6 years old. According to the cumulative curves, our results demonstrated that the myopic incidence in the IVIG group was significantly lower than the aspirin group (hazard ratio: 0.59, 95% confidence intervals: 0.36~0.96, p = 0.02). Treatment with IVIG for KD patients may have benefit for myopia control. Conclusion: Compared to aspirin, IVIG may decrease the myopic risk in KD patients. However, it needs further investigation including clinical vision survey of myopia due to the limitations of this population-based study. MDPI 2021-03-30 /pmc/articles/PMC8037584/ /pubmed/33808075 http://dx.doi.org/10.3390/jcm10071381 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Yu, Hun-Ju
Chuang, Meng-Ni
Chu, Chiao-Lun
Wu, Pei-Lin
Ho, Shu-Chen
Kuo, Ho-Chang
Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title_full Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title_fullStr Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title_full_unstemmed Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title_short Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
title_sort intravenous immunoglobulin treatment in kawasaki disease decreases the incidence of myopia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037584/
https://www.ncbi.nlm.nih.gov/pubmed/33808075
http://dx.doi.org/10.3390/jcm10071381
work_keys_str_mv AT yuhunju intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia
AT chuangmengni intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia
AT chuchiaolun intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia
AT wupeilin intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia
AT hoshuchen intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia
AT kuohochang intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia